Vasculitis and Thrombophlebitis Medication
- Author: Nadia Jennifer Chiara Luca, MD; Chief Editor: Lawrence K Jung, MD more...
Corticosteroids
Class Summary
These agents have potent immunosuppressive activity with rapid onset of action.
Prednisone (Deltasone, Sterapred)
Used to control acute symptoms and laboratory evidence of inflammation. May decrease inflammation by reversing increased capillary permeability and suppressing PMN activity. Stabilizes lysosomal membranes and also suppresses lymphocytes and antibody production.
Immunomodulators
Class Summary
IVIG is used as first-line therapy for Kawasaki disease; it decreases risk of coronary artery aneurysms.
Immune globulin, intravenous (Sandoglobulin, Gamimune, Gamunex, Gammar-P)
Multiple mechanisms. May absorb superantigens or toxins in Kawasaki disease. May saturate available Fc receptors. May block cytokines, cytokine receptors, or both. May absorb complement activation products. May down-regulate immunoglobulin synthesis. Blocks Fc receptors on macrophages. Suppresses inducer T and B cells and augments suppressor T cells. Blocks complement cascade. May increase CSF IgG (10%).
Immunosuppressant Agents
Class Summary
These agents help control inflammatory signs and symptoms.
Azathioprine (Imuran)
Imidazolyl derivative of 6-mercaptopurine. Many of biological effects are similar to those of parent compound. Both compounds are rapidly eliminated from blood and are oxidized or methylated in erythrocytes and liver. No azathioprine or mercaptopurine is detectable in urine 8 h after taken. Antagonizes purine metabolism and inhibits synthesis of DNA, RNA, and proteins. Mechanism whereby azathioprine affects autoimmune diseases is unknown. Works primarily on T cells. Suppresses hypersensitivities of cell-mediated type and causes variable alterations in antibody production. Immunosuppressive, delayed hypersensitivity, and cellular cytotoxicity tests are suppressed to a greater degree than antibody responses. Works very slowly; may require 6-12 mo of trial prior to effect. As many as 10% of patients may have idiosyncratic reaction disallowing use. Do not allow WBC count to drop below 3000/mL or lymphocyte count to drop below 1000/mL. Available in tablet form for PO administration or in 100-mg vials for IV injection
Cyclophosphamide (Cytoxan)
Cyclic polypeptide that suppresses some humoral activity. Chemically related to nitrogen mustards. Activated in the liver to its active metabolite, 4-hydroxycyclophosphamide, which alkylates the target sites in susceptible cells in an all-or-none type reaction. As an alkylating agent, the mechanism of action of the active metabolites may involve cross-linking of DNA, which may interfere with growth of normal and neoplastic cells. Biotransformed by cytochrome P-450 system to hydroxylated intermediates that break down to active phosphoramide mustard and acrolein. Interaction of phosphoramide mustard with DNA considered cytotoxic. When used in autoimmune diseases, mechanism of action is thought to involve immunosuppression due to destruction of immune cells via DNA cross-linking. In high doses, affects B cells by inhibiting clonal expansion and suppression of production of immunoglobulins. With long-term low-dose therapy, affects T-cell functions.
Methotrexate (Rheumatrex, Folex)
Antimetabolite that inhibits dihydrofolate reductase, thereby hindering DNA synthesis and cell reproduction. Effects may also be mediated by adenosine via the inhibition of aminoimidazole carboxamide ribonucleotide (AICAR) transformylase, leading to increased release of adenosine. Adjust dose gradually to attain satisfactory response.
Mycophenolate mofetil (CellCept); Mycophenolic acid (MyFortic)
Inhibits inosine monophosphate dehydrogenase and suppresses de novo purine synthesis by lymphocytes, thereby inhibiting their proliferation. Inhibits antibody production.
Two formulations are available and are notinterchangeable. The original formulation, mycophenolate mofetil (MMF, Cellcept) is a prodrug that once hydrolyzed in vivo, releases the active moiety mycophenolic acid. A newer formulation, mycophenolic acid (MPA, Myfortic) is an enteric-coated product that delivers the active moiety.
Tumor Necrosis Factor Inhibitor
Class Summary
Blocks the process by which activated neutrophils adhere to endothelium and stimulate lysis of endothelial cells in the presence of TNF-alpha.
Infliximab (Remicade)
Chimeric IgG1k monoclonal antibody that neutralizes cytokine TNF-alpha and inhibits its binding to TNF-alpha receptor. Reduces infiltration of inflammatory cells and TNF-alpha production in inflamed areas.
Anti-B lymphocyte agent
Class Summary
May consider these agents for conditions refractory to other treatments.
Rituximab (Rituxan)
Chimeric IgG1-kappa monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The Fab domain binds to CD20 antigen on B lymphocytes, and the Fc domain recruits immune effector functions to mediate B-cell lysis in vitro. Possible mechanisms of cell lysis include complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC).
Anticoagulant
Class Summary
These agents provide immediate and long-term treatment of vascular thrombosis.
Heparin
Augments activity of antithrombin III and prevents conversion of fibrinogen to fibrin. Does not actively lyse but is able to inhibit further thrombogenesis. Prevents reaccumulation of clot after spontaneous fibrinolysis.
Provide as continuous heparin infusion to maintain aPTT at 1.5 times the control.
Enoxaparin (Lovenox)
Low molecular weight heparin. Augments activity of antithrombin III and prevents conversion of fibrinogen to fibrin. Does not actively lyse but is able to inhibit further thrombogenesis. Prevents reaccumulation of clot after spontaneous fibrinolysis.
Advantages include intermittent dosing and decreased requirement for monitoring. Heparin anti–factor Xa levels may be obtained if needed to establish adequate dosing.
Warfarin (Coumadin)
Interferes with hepatic synthesis of vitamin K–dependent coagulation factors.
Antibiotics
Class Summary
Prophylaxis for P jiroveci with cyclophosphamide therapy.
Trimethoprim-sulfamethoxazole (Bactrim, Septra)
As P jiroveci prophylaxis for patients taking cyclophosphamide. Dihydrofolate reductase inhibitor in combination with sulfonamide.
Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. Feb 1994;37(2):187-92. [Medline].
Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med. Nov 20 1997;337(21):1512-23. [Medline].
[Best Evidence] Ozen S, Ruperto N, Dillon MJ, Bagga A, Barron K, Davin JC. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis. Jul 2006;65(7):936-41. [Medline].
Ozen S, Anton J, Arisoy N, Bakkaloglu A, Besbas N, Brogan P. Juvenile polyarteritis: results of a multicenter survey of 110 children. J Pediatr. Oct 2004;145(4):517-22. [Medline].
[Best Evidence] Akikusa JD, Schneider R, Harvey EA, Hebert D, Thorner PS, Laxer RM. Clinical features and outcome of pediatric Wegener's granulomatosis. Arthritis Rheum. Jun 15 2007;57(5):837-44. [Medline].
Peco-Antic A, Bonaci-Nikolic B, Basta-Jovanovic G. Childhood microscopic polyangiitis associated with MPO-ANCA. Pediatr Nephrol. Oct 27 2005;[Medline].
Boyer D, Vargas SO, Slattery D, Rivera-Sanchez YM, Colin AA. Churg-Strauss syndrome in children: a clinical and pathologic review. Pediatrics. Sep 2006;118(3):e914-20. [Medline].
Sarica-Kucukoglu R, Akdag-Kose A, KayabalI M, Yazganoglu KD, Disci R, Erzengin D. Vascular involvement in Behçet's disease: a retrospective analysis of 2319 cases. Int J Dermatol. Aug 2006;45(8):919-21. [Medline].
Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. N Engl J Med. Jul 10 2003;349(2):160-9. [Medline].
Dedeoglu F, Sundel RP. Vasculitis in children. Rheum Dis Clin North Am. Aug 2007;33(3):555-83. [Medline].
[Best Evidence] Jennette JC, Falk RJ. New insight into the pathogenesis of vasculitis associated with antineutrophil cytoplasmic autoantibodies. Curr Opin Rheumatol. Jan 2008;20(1):55-60. [Medline].
Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest. Oct 2002;110(7):955-63. [Medline].
Lau KK, Wyatt RJ, Moldoveanu Z, Tomana M, Julian BA, Hogg RJ. Serum levels of galactose-deficient IgA in children with IgA nephropathy and Henoch-Schönlein purpura. Pediatr Nephrol. Dec 2007;22(12):2067-72. [Medline].
Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet. Oct 19 2002;360(9341):1197-202. [Medline].
Wu M-H, Nakamura Y, Burns JC, et al. State-of-the-art basic and clinical science of Kawasaki disease. Pediatric Health. 2008;2:405-409.
Cabral DA, Uribe AG, Benseler S, O'Neil KM, Hashkes PJ, Higgins G. Classification, presentation, and initial treatment of Wegener's granulomatosis in childhood. Arthritis Rheum. Nov 2009;60(11):3413-24. [Medline].
Phillip R, Luqmani R. Mortality in systemic vasculitis: a systematic review. Clin Exp Rheumatol. Sep-Oct 2008;26(5 Suppl 51):S94-104. [Medline].
Narchi H. Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child. Sep 2005;90(9):916-20. [Medline].
Elbers J, Benseler SM. Central nervous system vasculitis in children. Curr Opin Rheumatol. Jan 2008;20(1):47-54. [Medline].
Reiff A. Ocular complications of childhood rheumatic diseases: nonuveitic inflammatory eye diseases. Curr Rheumatol Rep. Jul 2009;11(3):226-32. [Medline].
Avcin T, Cimaz R, Rozman B. The Ped-APS Registry: the antiphospholipid syndrome in childhood. Lupus. Sep 2009;18(10):894-9. [Medline].
Levine D, Akikusa J, Manson D, Silverman E, Schneider R. Chest CT findings in pediatric Wegener's granulomatosis. Pediatr Radiol. Jan 2007;37(1):57-62. [Medline].
Kim YK, Lee KS, Chung MP, Han J, Chong S, Chung MJ. Pulmonary involvement in Churg-Strauss syndrome: an analysis of CT, clinical, and pathologic findings. Eur Radiol. Dec 2007;17(12):3157-65. [Medline].
Lauque D, Cadranel J, Lazor R, Pourrat J, Ronco P, Guillevin L. Microscopic polyangiitis with alveolar hemorrhage. A study of 29 cases and review of the literature. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P). Medicine (Baltimore). Jul 2000;79(4):222-33. [Medline].
Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics. Dec 1995;96(6):1057-61. [Medline].
Weiss PF, Feinstein JA, Luan X, Burnham JM, Feudtner C. Effects of corticosteroid on Henoch-Schönlein purpura: a systematic review. Pediatrics. Nov 2007;120(5):1079-87. [Medline].
[Best Evidence] Chartapisak W, Opastirakul S, Hodson EM, Willis NS, Craig JC. Interventions for preventing and treating kidney disease in Henoch-Schönlein Purpura (HSP). Cochrane Database Syst Rev. 2009;(3):CD005128. [Medline].
[Guideline] Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. Mar 2009;68(3):310-7. [Medline].
[Guideline] Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. Mar 2009;68(3):318-23. [Medline].
Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med. Jan 15 2006;173(2):180-7. [Medline].
Filocamo G, Buoncompagni A, Viola S, Loy A, Malattia C, Ravelli A. Treatment of Takayasu's arteritis with tumor necrosis factor antagonists. J Pediatr. Sep 2008;153(3):432-4. [Medline].
Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum. Dec 15 2007;57(8):1487-95. [Medline].
McCrindle BW. Kawasaki disease: a childhood disease with important consequences into adulthood. Circulation. Jul 7 2009;120(1):6-8. [Medline].
Newburger JW, Takahashi M, Gerber MA. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. Oct 26 2004;110(17):2747-71. [Medline].
Benseler SM, deVeber G, Hawkins C, Schneider R, Tyrrell PN, Aviv RI, et al. Angiography-negative primary central nervous system vasculitis in children: a newly recognized inflammatory central nervous system disease. Arthritis Rheum. Jul 2005;52(7):2159-67. [Medline].
Cantez S, Benseler SM. Childhood CNS vasculitis: a treatable cause of new neurological deficit in children. Nat Clin Pract Rheumatol. Sep 2008;4(9):460-1. [Medline].
[Best Evidence] Jennette JC, Xiao H, Falk RJ. Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol. May 2006;17(5):1235-42. [Medline].
Lee BB, Laredo J, Neville R, Villavicencio JL. Endovascular management of takayasu arteritis: is it a durable option?. Vascular. May-Jun 2009;17(3):138-46. [Medline].
McCrindle BW, McIntyre S, Kim C, Lin T, Adeli K. Are patients after Kawasaki disease at increased risk for accelerated atherosclerosis?. J Pediatr. Sep 2007;151(3):244-8, 248.e1. [Medline].
Roediger FC, Orloff LA, Courey MS. Adult subglottic stenosis: management with laser incisions and mitomycin-C. Laryngoscope. Sep 2008;118(9):1542-6. [Medline].
| Category | Definition |
| Localized | Upper and/or lower respiratory tract disease without any other systemic involvement or constitutional symptoms |
| Early systemic | Any, without organ-threatening or life-threatening disease |
| Generalized | Renal or other organ-threatening disease, serum creatinine >500 μmol/L (5.6 mg/dL) |
| Severe | Renal or other vital organ failure, serum creatinine >500 μmol/L (5.6 mg/dL) |
| Refractory | Progressive disease unresponsive to glucocorticoids and cyclophosphamide |
Print
